Cargando…
The never ending success story of tranexamic acid in acquired bleeding
Tranexamic acid (TXA) is an anti-fibrinolytic agent that acts by inhibiting plasminogen activation and fibrinolysis. Although its first clinical use dates back more than 50 years, this hemostatic agent is still the object of intense clinical and developmental research. In particular, renewed interes...
Autores principales: | Franchini, Massimo, Mannucci, Pier Mannuccio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193503/ https://www.ncbi.nlm.nih.gov/pubmed/32336684 http://dx.doi.org/10.3324/haematol.2020.250720 |
Ejemplares similares
-
Acquired von Willebrand syndrome: focused for hematologists
por: Franchini, Massimo, et al.
Publicado: (2020) -
Bleeding Disorders in Primary Fibrinolysis
por: Franchini, Massimo, et al.
Publicado: (2021) -
Past, present and future of hemophilia: a narrative review
por: Franchini, Massimo, et al.
Publicado: (2012) -
Health Effects of Ambient Air Pollution in Developing Countries
por: Mannucci, Pier Mannuccio, et al.
Publicado: (2017) -
Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016)